Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125922611 | 12592261 | 1 | I | 20160721 | 20160726 | 20160726 | EXP | BR-ROCHE-1800233 | ROCHE | 0.00 | M | Y | 78.00000 | KG | 20160726 | PH | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125922611 | 12592261 | 1 | PS | XELODA | CAPECITABINE | 1 | Oral | DATE OF LAST INFUSION BEFORE THE HOSPITALIZATION: 09/JUN/2016 C1D1 (CYCLE 1, DAY 1) OF A PROTOCOL WI | U | 20896 | 3800 | MG | QD | ||||||
| 125922611 | 12592261 | 2 | SS | TEVAOXALI | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | DATE OF LAST INFUSION BEFORE THE HOSPITALIZATION: 09/JUN/2016 C1D1 (CYCLE 1, DAY 1) OF A PROTOCOL WI | U | 15G09OH | 0 | 249.47 | MG | ||||||
| 125922611 | 12592261 | 3 | SS | XARELTO | RIVAROXABAN | 1 | Unknown | Y | 0 | ||||||||||
| 125922611 | 12592261 | 4 | C | DIOVAN AMLO | AMLODIPINEVALSARTAN | 1 | 0 | ||||||||||||
| 125922611 | 12592261 | 5 | C | MAREVAN | WARFARIN SODIUM | 1 | 0 | ||||||||||||
| 125922611 | 12592261 | 6 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
| 125922611 | 12592261 | 7 | C | DIGESAN | BROMOPRIDE | 1 | 0 | ||||||||||||
| 125922611 | 12592261 | 8 | C | SIMETHICONE (DIMETHICONE) | DIMETHICONE | 1 | 0 | ||||||||||||
| 125922611 | 12592261 | 9 | C | NAUSEDRON | ONDANSETRON HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125922611 | 12592261 | 10 | C | IMOSEC | LOPERAMIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125922611 | 12592261 | 1 | Rectal cancer |
| 125922611 | 12592261 | 2 | Rectal cancer |
| 125922611 | 12592261 | 3 | Pulmonary embolism |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125922611 | 12592261 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125922611 | 12592261 | Dehydration | |
| 125922611 | 12592261 | Diarrhoea | |
| 125922611 | 12592261 | Electrolyte imbalance | |
| 125922611 | 12592261 | Gastrointestinal haemorrhage | |
| 125922611 | 12592261 | Haematuria | |
| 125922611 | 12592261 | Subileus | |
| 125922611 | 12592261 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |